Nuvalent’s $300M offering; Spark ends epilepsy deal; A small IPO
Nuvalent initiates $300M public offering: The cancer biotech on Monday announced a $300 million offering of its common stock. The move follows the company’s early Phase I results last Friday for its ALK-selective tyrosine kinase inhibitor candidate, NVL-655, in ALK-positive non-small cell lung cancer patients. The drug reached a 39% objective response rate in the 51 patients evaluable at data cut-off, although a handful of responses have yet to be confirmed. — Ayisha Sharma
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
